PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

交易中 04-19 15:29:05 EDT

20.53

-0.30

-1.46%

最高21.01	最低20.49	成交量57.68万
今开20.62	昨收20.83	日振幅2.50%
总市值19.04亿	流通市值18.18亿	总股本9,275万
成交额1,193万	换手率0.65%	流通股本8,855万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":20.525,"timestamp":1713554938415,"preClose":20.83,"halted":0,"volume":576819,"delay":0,"floatShares":88552057,"shares":92751590,"eps":-0.885381,"marketStatus":"交易中","marketStatusCode":2,"change":-0.305,"latestTime":"04-19 15:29:05 EDT","open":20.62,"high":21.01,"low":20.49,"amount":11933196.286041,"amplitude":0.024964,"askPrice":20.53,"askSize":579,"bidPrice":20.52,"bidSize":244,"shortable":3,"etf":0,"ttmEps":-0.885381,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1713556800000},"adr":0,"listingDate":1554955200000,"adjPreClose":20.83,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":20.82,"preClose":20.83,"latestTime":"09:16 EDT","volume":7,"amount":144.509995,"timestamp":1713532613717},"postHourTrading":{"tag":"盘后","latestPrice":20.83,"preClose":20.83,"latestTime":"18:34 EDT","volume":388121,"amount":8084559.68,"timestamp":1713479693753},"volumeRatio":0.504499},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2427003766","title":"极摩客推出新款G5迷你主机 支持PD供电/USB-C供电","url":"https://stock-news.laohu8.com/highlight/detail?id=2427003766","media":"IT 商业新闻网","top":-1,"share":"https://www.laohu8.com/m/news/2427003766?lang=zh_cn&edition=full","pubTime":"2024-04-15 17:28","pubTimestamp":1713173318,"startTime":"0","endTime":"0","summary":"原标题：极摩客推出新款 G5 迷你主机：英特尔 N97 799 元起　　4 月 15 日消息，据极摩客官方微博，极摩客今天推出了新款 G5","market":"us","thumbnail":"https://q0.itc.cn/q_70/images03/20240415/3309e1a5762749acb9c0ecdb45db03f6.png","type":0,"news_type":0,"thumbnails":["https://q0.itc.cn/q_70/images03/20240415/3309e1a5762749acb9c0ecdb45db03f6.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.itxinwen.com/diannao/20240415/150010.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425026985","title":"君实生物PD-1获批肾癌一线治疗 未来或拓至大适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2425026985","media":"证券日报","top":-1,"share":"https://www.laohu8.com/m/news/2425026985?lang=zh_cn&edition=full","pubTime":"2024-04-08 11:03","pubTimestamp":1712545438,"startTime":"0","endTime":"0","summary":"本报记者徐一鸣见习记者金婉霞4月7日晚间，君实生物公告称，公司收到了国家药品监督管理局（NMPA）核准签发的《药品注册证书》，其特瑞普利单抗（商品名：拓益）联合阿昔替尼用于中高危的不可切除或转移性肾细胞癌患者的一线治疗的新适应症上市申请获得批准，这是我国首个获批的肾癌免疫疗法。新适应症的获批也意味着拓益的销售市场有望进一步拓宽。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404083035942363.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424962389","title":"2023年国产PD-1销售成绩单出炉：百济神州夺得销冠 复宏汉霖成为黑马","url":"https://stock-news.laohu8.com/highlight/detail?id=2424962389","media":"华夏时报","top":-1,"share":"https://www.laohu8.com/m/news/2424962389?lang=zh_cn&edition=full","pubTime":"2024-04-04 09:02","pubTimestamp":1712192544,"startTime":"0","endTime":"0","summary":"随着各家企业年报披露，国内PD-1业绩排名也浮出水面。2023年10月，君实生物PD-1抑制剂特瑞普利单抗正式获得美国食品药品监督管理局批准，成为首个出海美国的国产PD-1。赶超不容忽视的是，2023年，处于第二梯队的PD-1相关企业表现出了不断进击的势头。2023年6月，嘉和生物发布公告称，旗下PD-1杰诺单抗的新药上市申请未获批准，这是首次被拒批的国产PD-1。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040409054487dca740&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040409054487dca740&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2423214294","title":"信达生物(01801)抗CTLA-4单抗+抗PD-1单抗拟纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2423214294","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2423214294?lang=zh_cn&edition=full","pubTime":"2024-03-30 09:44","pubTimestamp":1711763080,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月29日，中国国家药监局药品审评中心官网公示，信达生物IBI310及信迪利单抗两款产品拟纳入突破性治疗品种，针对适应症为IBI310联合信迪利单抗用于可切除的高微卫星不稳定性或错配修复基因缺陷型结肠癌的新辅助治疗。据悉，IBI310是信达生物自主研发的重组全人源抗CTLA-4单克隆抗体注射液。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1096655.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422725589","title":"基石药业2023年年报：ADC等早期管线推进迅速 PD-L1出海取得实质性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2422725589","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2422725589?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:37","pubTimestamp":1711586251,"startTime":"0","endTime":"0","summary":"【基石药业2023年年报：ADC等早期管线推进迅速 PD-L1出海取得实质性进展】3月27日晚，港股创新药企基石药业（02616.HK）公布了2023年年度业绩及近期业务进展。公告显示，2023年基石药业总收入为4.638亿元人民币，其中商业化收入3.681亿元人民币；公司财务状况稳健，截至2023年12月31日现金储备为10.3亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202403283027024982.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403283027024982.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421440042","title":"Pagerduty, Inc.盘中异动 早盘股价大涨5.07%报23.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2421440042","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421440042?lang=zh_cn&edition=full","pubTime":"2024-03-21 22:28","pubTimestamp":1711031287,"startTime":"0","endTime":"0","summary":"北京时间2024年03月21日22时28分，Pagerduty, Inc.股票出现异动，股价急速拉升5.07%。截至发稿，该股报23.61美元/股，成交量81.7904万股，换手率0.88%，振幅4.09%。Pagerduty, Inc.股票所在的软件服务行业中，整体涨幅为1.04%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403212228077a4e42f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403212228077a4e42f8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420747129","title":"Pagerduty, Inc.盘中异动 早盘股价大涨5.22%报22.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420747129","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420747129?lang=zh_cn&edition=full","pubTime":"2024-03-18 21:30","pubTimestamp":1710768626,"startTime":"0","endTime":"0","summary":"北京时间2024年03月18日21时30分，Pagerduty, Inc.股票出现波动，股价大幅上涨5.22%。截至发稿，该股报22.36美元/股，成交量8.1947万股，换手率0.09%，振幅0.84%。Pagerduty, Inc.股票所在的软件服务行业中，整体涨幅为0.00%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240318213026791b34ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240318213026791b34ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419337970","title":"BUZZ-PagerDuty 在预测失误后暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2419337970","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419337970?lang=zh_cn&edition=full","pubTime":"2024-03-15 22:19","pubTimestamp":1710512345,"startTime":"0","endTime":"0","summary":"    3月15日 - ** 数字运营管理平台预期令人失望，PagerDuty公司  股价下跌9.3%，报20.79美元** 股价创逾4个月新低，单日跌幅为6月2日以来最大** 周四晚些时候，该公司预计  2025 财年的营业收入为 4.7 - 4.78 亿美元，年增长率为 9% - 11%，每股收益为 0.65 - 0.70 美元，而 LSEG 预计为 4.807 亿美元和 0.82 美元。** 第四季度营业额为 1.111 亿美元，每股收益为 0.17 美元，高于一致预期的 1.104 亿美元和 0.15 美元。** 公司称第四季度年度经常性收入 同比增长 10%，达到 4.519 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419091108","title":"辉瑞择捷美第五个适应症获批，成为首个治疗胃癌的PD-L1抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2419091108","media":"新民晚报","top":-1,"share":"https://www.laohu8.com/m/news/2419091108?lang=zh_cn&edition=full","pubTime":"2024-03-15 14:25","pubTimestamp":1710483932,"startTime":"0","endTime":"0","summary":"辉瑞公司今天宣布，肿瘤免疫创新药择捷美已获国家药品监督管理局批准，联合含氟尿嘧啶类和铂类药物化疗用于表达PD-L1的不可手术切除的局部晚期或转移性胃及胃食管结合部腺癌的一线治疗，成为全球首个在胃/胃食管结合部腺癌适应症获批的PD-L1单抗。这是继食管鳞癌之后，择捷美于近期在上消化道肿瘤领域获批的第二项适应症，也是择捷美自2021年以来获批的第五项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151426298b363ce2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151426298b363ce2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419299727","title":"百济神州PD-1获FDA批准 系君实生物之后中国第二款","url":"https://stock-news.laohu8.com/highlight/detail?id=2419299727","media":"央广网","top":-1,"share":"https://www.laohu8.com/m/news/2419299727?lang=zh_cn&edition=full","pubTime":"2024-03-15 12:03","pubTimestamp":1710475400,"startTime":"0","endTime":"0","summary":"央广网北京3月15日消息（记者曹倩实习生谢晓萱）今日，百济神州宣布，其PD-1抑制剂替雷利珠单抗已获FDA上市，用于治疗既往经化疗后进展的晚期或转移性食管磷状细胞癌（ESCC），商品名为Tevimbra。央广资本眼关注到，继君实生物的特瑞普利单抗被FDA批准为首个鼻咽癌治疗药物之后，百济神州的替雷利珠单抗成为第二款成功出海美国的国产PD-1。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403153013461773.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419026999","title":"百济神州PD-1美国获批，商业化挑战刚刚开始 | 见智研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2419026999","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2419026999?lang=zh_cn&edition=full","pubTime":"2024-03-15 10:42","pubTimestamp":1710470547,"startTime":"0","endTime":"0","summary":"能否瓜分K药250亿美金市场？","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/08e2dc16-8fa6-4eae-82b9-33b08c10b1fc.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/08e2dc16-8fa6-4eae-82b9-33b08c10b1fc.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3710482","is_publish_highlight":false,"gpt_icon":0},{"id":"2419878316","title":"Brainstorm Cell Therapeutics Inc.盘中异动 早盘急速上涨6.78%报0.329美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419878316","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419878316?lang=zh_cn&edition=full","pubTime":"2024-03-13 21:32","pubTimestamp":1710336744,"startTime":"0","endTime":"0","summary":"北京时间2024年03月13日21时32分，Brainstorm Cell Therapeutics Inc.股票出现异动，股价急速上涨6.78%。截至发稿，该股报0.329美元/股，成交量2.2471万股，换手率0.05%，振幅0.32%。Brainstorm Cell Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.61%。其相关个股中，Nucana Plc、Kintara Therapeutics, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Kintara Therapeutics, Inc.、Nucana Plc、Revelation Biosciences, Inc.较为活跃，换手率分别为92.41%、38.12%、14.37%，振幅较大的相关个股有Nucana Plc、Kintara Therapeutics, Inc.、Cybin Inc.，振幅分别为18.20%、17.94%、12.89%。Brainstorm Cell Therapeutics Inc.公司简介：Brainstorm Cell Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313213224877cbcf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313213224877cbcf8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419100560","title":"PagerDuty Inc   预计每股收益15美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2419100560","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419100560?lang=zh_cn&edition=full","pubTime":"2024-03-13 04:15","pubTimestamp":1710274523,"startTime":"0","endTime":"0","summary":"   * PagerDuty公司   将于3月14日公布截至2024年1月31日的财报，预计该公司的季度营收将出现增长。* 根据LSEG的数据，8位分析师的平均预期显示，这家总部位于加利福尼亚州旧金山的公司的营收将从去年同期的1.0097亿美元增至1.10433亿美元，增幅为9.3%。* LSEG分析师对PagerDuty公司的平均预期为每股收益15美分。* 华尔街对 PagerDuty Inc 的 12 个月目标价中位数为 29.41 美元，高于其最新收盘价 23.85 美元。3月12日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417637230","title":"Brainstorm Cell Therapeutics Inc.盘中异动 急速下挫5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417637230","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417637230?lang=zh_cn&edition=full","pubTime":"2024-03-08 23:10","pubTimestamp":1709910653,"startTime":"0","endTime":"0","summary":"北京时间2024年03月08日23时10分，Brainstorm Cell Therapeutics Inc.股票出现异动，股价快速下跌5.06%。Brainstorm Cell Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.50%。其相关个股中，Psyence Biomedical Ltd.、Psyence Biomedical Ltd C/Wts 25/01/2029、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 涨幅较大，Psyence Biomedical Ltd.、Scisparc Ltd.、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为571.54%、223.78%、197.50%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Psyence Biomedical Ltd.、知临集团，振幅分别为146.50%、124.41%、64.66%。Brainstorm Cell Therapeutics Inc.公司简介：Brainstorm Cell Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030823105487e77580&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030823105487e77580&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":-0.0872},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.1945},{"period":"6month","weight":0.0601},{"period":"1year","weight":-0.4026},{"period":"ytd","weight":-0.1002}],"compareEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0314},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.186},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.0509}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律注册成立。PagerDuty是数字企业的中枢神经系统。PagerDuty利用几乎任何支持软件的系统或设备的数字信号，将其与人工响应数据相结合，并协调团队实时采取正确的行动。公司的产品可帮助组织改善运营，加速创新，增加收入，降低安全风险并提供出色的客户体验。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.052063},{"month":2,"riseRate":0.6,"avgChangeRate":-0.030334},{"month":3,"riseRate":0.4,"avgChangeRate":-0.028164},{"month":4,"riseRate":0.4,"avgChangeRate":-0.021905},{"month":5,"riseRate":0.4,"avgChangeRate":0.0158},{"month":6,"riseRate":0.6,"avgChangeRate":-0.025549},{"month":7,"riseRate":0.6,"avgChangeRate":0.031422},{"month":8,"riseRate":0.6,"avgChangeRate":0.002566},{"month":9,"riseRate":0,"avgChangeRate":-0.144809},{"month":10,"riseRate":0.4,"avgChangeRate":-0.040139},{"month":11,"riseRate":0.6,"avgChangeRate":0.044973},{"month":12,"riseRate":0.6,"avgChangeRate":0.069164}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}